Benoit You

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (14)

Maaike van der Aa

Netherlands Comprehensive Cancer Organisation

NETHERLANDS

View details

François Bertucci

Aix-Marseille University

FRANCE

View details

Laetitia COLLET

Université libre de Bruxelles

BELGIUM

View details

Larry Copeland

Professor

Ohio State University

UNITED STATES

View details

Frédéric Thomas

FRANCE

View details

Iain McNeish

Imperial College London

UNITED KINGDOM

View details

Guy Jerusalem

BELGIUM

View details

isabelle ray coquard

professor

FRANCE

View details

Christophe Le Tourneau

Head of Early Phase Clinical Trials

Institut Curie

FRANCE

View details

Caroline Kelly

Head of Biostatistics

UNITED KINGDOM

View details

Anthony Gonçalves

Aix-Marseille University

FRANCE

View details

Sung-Bae Kim

University of Ulsan College of Medicine

SOUTH KOREA

View details

Maud Kamal

Institut Gustave Roussy

FRANCE

View details

Jean-Yves Blay

University Professor, Medical Oncology

Université Claude Bernard Lyon 1 - Domaine de Rockefeller

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Benoit You

Research Interests

Explore related searches

Contact this professor

Articles (11)

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Predominance of <i>BRCA2</i> Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with <i>BRCA1</i> or <i>BRCA2</i> Mutation

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program

Collaborators (14)

Maaike van der Aa

François Bertucci

Laetitia COLLET

Larry Copeland

Frédéric Thomas

Iain McNeish

Guy Jerusalem

isabelle ray coquard

Christophe Le Tourneau

Caroline Kelly

Anthony Gonçalves

Sung-Bae Kim

Maud Kamal

Jean-Yves Blay

Make your next move.